phlda3 Antibody

What is PHLDA3 and why is it significant in cellular signaling research?

PHLDA3 (Pleckstrin homology-like domain family A member 3) functions as a p53/TP53-regulated repressor of Akt/AKT1 signaling. Its significance lies in its mechanism of action, where it represses AKT1 by preventing its binding to membrane lipids, thereby inhibiting AKT1 translocation to the cellular membrane and activation. PHLDA3 contributes to p53/TP53-dependent apoptosis through this AKT1 repression, which explains how p53/TP53 can negatively regulate AKT1. Based on these functions, PHLDA3 is considered a potential tumor suppressor .

The protein is expressed in various tissues throughout the body including the brain, lungs, and liver, indicating its diverse cellular functions . Research has demonstrated its upregulation under various stress conditions, making it an important marker for cellular stress responses. PHLDA3 is also known by alternative names including TIH1 and TDAG51/Ipl homolog, and it belongs to a family that includes PHLDA1 and PHLDA2 .

What are the optimal methods for detecting PHLDA3 expression in tissue samples?

For detecting PHLDA3 in research applications, several validated methods have proven effective:

Western Blotting:

• Mouse monoclonal antibodies such as anti-PHLDA3 antibody [4B6] (ab81464) are suitable for detecting human PHLDA3

• Expected band size is approximately 14 kDa

• Protein extracts should be prepared carefully, separated by 10% SDS-PAGE, and transferred to PVDF membranes

• For optimal results, use antibody dilutions of 1:1000 for primary antibodies and 1:20,000 for secondary antibodies

Immunohistochemistry/Immunofluorescence:

• Cells should be fixed in 4% paraformaldehyde for 15 minutes, permeabilized with PBS-Triton 0.05%, and blocked with 5% BSA

• Goat polyclonal anti-PHLDA3 antibody (ab22822) used at 1:70 dilution in 1% BSA has shown good results for immunostaining

• Overnight incubation at 4°C provides optimal antibody binding

• Inactivate endogenous peroxidases with 3% H₂O₂ before detection for cleaner results

When troubleshooting, verify antibody specificity using positive controls such as samples from cells treated with stress inducers that upregulate PHLDA3 (cytokines, palmitate, thapsigargin, or ribose), which have been shown to markedly increase PHLDA3 expression .

How is PHLDA3 expression regulated during cellular stress?

PHLDA3 expression demonstrates dynamic regulation during various cellular stress conditions, making it an excellent marker for stress response studies:

Inflammatory Stress:
Exposure of beta cells to proinflammatory cytokines (IL1β, IFNγ, TNFα) markedly upregulates PHLDA3 mRNA and protein levels, concurrent with induction of ER stress genes (Ddit3, Trb3) and antioxidant genes (Hmox1) . This suggests PHLDA3 participates in the inflammatory stress response pathway.

Metabolic Stress:
Treatment with palmitate (a saturated fatty acid) significantly increases PHLDA3 expression in beta cells, paralleling the induction of stress-response genes . Prolonged exposure to elevated glucose levels (30 mmol/l versus 10 mmol/l) in mouse islets also markedly upregulates PHLDA3 mRNA levels, indicating its role in glucotoxicity responses .

ER Stress:
The pharmacological ER stress inducer thapsigargin strongly upregulates PHLDA3 mRNA levels in parallel with both adaptive (Hspa5, Hsp90b1, Fkbp11) and proapoptotic (Ddit3, Trb3) unfolded protein response genes . This confirms PHLDA3 as a novel ER stress-responsive gene in beta cells.

Oxidative Stress:
Ribose treatment, which produces reactive oxygen species more potently than glucose, strongly upregulates PHLDA3 expression alongside antioxidant genes (Hmox1, Gpx1, Srxn1) . H₂O₂ treatment also markedly increases PHLDA3 immunostaining in human islets .

Mechanistically, the adaptive UPR effector Xbp1 is required for PHLDA3 induction under stress conditions, while the pro-apoptotic effector Ddit3 inhibits its expression, suggesting complex transcriptional regulation .

What methodological approaches are recommended for studying PHLDA3's role in vascular development?

When investigating PHLDA3's role in vascular development, researchers should consider these methodological approaches based on zebrafish model studies:

Transgenic Models:

• Utilize transgenic zebrafish lines such as tg(flk1:GFP) and tg(fli:GFP) that express fluorescent markers in vascular structures to visualize vascular development in real-time

• These models allow direct observation of impaired intersegmental vessel (ISV) development following PHLDA3 overexpression

mRNA Overexpression:

• Synthesize and inject PHLDA3 mRNA to achieve overexpression in zebrafish embryos

• Include appropriate controls such as mCherry mRNA injection and uninjected embryos for comparison

• Focus analysis on hemangioblast specification and ISV development, as these processes are particularly sensitive to PHLDA3 levels

Gene Expression Analysis:

• Employ whole mount in situ hybridization using antisense RNA probes to detect vascular markers:

  • Hemangioblast markers: scl, fli1, etsrp

  • ISV markers: flk1, cdh5

  • Venous markers: flt4, dab2

• Develop specific probes using RT-PCR with primers targeting PHLDA3 (forward: 5'-TGGAGTATAAACGGGGTCTG-3', reverse: 5'-GCAAAGTGAGGAGTGGAATC-3')

Signaling Pathway Analysis:

• Assess AKT activation status through western blot analysis using anti-phosphorylated-AKT (Ser473) and total AKT antibodies

• Consider rescue experiments using constitutively active forms of AKT to confirm PHLDA3's mechanism of action through AKT inhibition

• Extract protein from approximately 80 embryos at 24 hpf stage for sufficient protein quantity

When interpreting results, note that while PHLDA3 overexpression inhibits hemangioblast specification and ISV development, knockdown approaches may not show pronounced effects due to possible functional redundancy with PHLDA1 and PHLDA2 family members .

How can I effectively investigate PHLDA3's role in diabetes and beta cell survival?

To investigate PHLDA3's role in diabetes and beta cell survival, employ these research strategies:

Diabetic Model Systems:

• Compare PHLDA3 expression between diabetic and non-diabetic models:

  • Type 2 diabetes: db/db mice versus age-matched lean C57BL/KsJ mice

  • Type 1 diabetes: NOD mice versus control Balb/c mice

  • Human: islets from type 2 diabetes donors versus control subjects

In Vitro Stress Models:

• Treat MIN6 cells or isolated islets with diabetic milieu factors:

  • Inflammatory stress: cytokines (IL1β, IFNγ, TNFα)

  • Metabolic stress: saturated fatty acids (palmitate)

  • ER stress: thapsigargin

  • Oxidative stress: ribose or H₂O₂

Gene Knockdown Approaches:

• Use siRNA-mediated knockdown of PHLDA3 to assess its protective role

• Evaluate effects on apoptosis, inflammatory gene expression (iNos, IL1β, IκBα), NFκB phosphorylation, antioxidant gene expression (Gpx1, Srxn1), and UPR gene expression (Xbp1, Hspa5, Fkbp11)

Regulatory Pathway Analysis:

• Investigate the relationship between PHLDA3 and UPR mediators:

  • Knock down Xbp1 to assess its requirement for PHLDA3 induction

  • Knock down Ddit3 to examine its inhibitory effect on PHLDA3 expression

Data Analysis Considerations:

• When interpreting results, evaluate PHLDA3 expression patterns in relation to:

  • Stress intensity and duration

  • Cell viability and apoptosis markers

  • Activation of downstream signaling pathways

  • Expression of stress-response genes

This research is particularly significant as PHLDA3 expression is markedly upregulated in islets from diabetic humans and mice, suggesting its potential role in beta cell adaptation to diabetic stress conditions .

What are the critical considerations when optimizing PHLDA3 antibody use in Western blotting?

When optimizing PHLDA3 antibody use in Western blotting, consider these critical factors:

Sample Preparation:

• Extract proteins carefully from tissues or cells; for zebrafish embryo studies, approximately 80 embryos at 24 hpf stage provides sufficient protein

• Separate proteins using 10% SDS-PAGE for optimal resolution of the 14 kDa PHLDA3 protein

• Transfer to PVDF membranes, which have shown good results with PHLDA3 antibodies

Antibody Selection and Optimization:

• Mouse monoclonal anti-PHLDA3 antibody [4B6] (ab81464) has been validated for human PHLDA3 detection

• Optimal dilution ratios: use primary antibodies at 1:1000 and secondary antibodies at 1:20,000

• For phospho-protein detection in signaling studies (e.g., AKT pathway), use Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb #4060 at 1:1000 dilution

Positive Controls:

• Include samples from cells treated with known PHLDA3 inducers:

  • Ad-p53 treated cells show clear PHLDA3 induction

  • Cytokine, palmitate, thapsigargin or ribose-treated cells/islets demonstrate significant PHLDA3 upregulation

Detection Systems:

• Use enhanced chemiluminescence with SuperSignal West Pico Chemiluminescent Substrate for optimal sensitivity

• Image using a high-sensitivity system such as ChemiDoc XRS (Bio-Rad) for reliable detection

Troubleshooting:

• If experiencing weak signal: increase antibody concentration, extend incubation time, or use more sensitive detection reagents

• If detecting non-specific bands: increase blocking time, optimize antibody dilution, or consider using different blocking reagents

• For verification of specificity: include PHLDA3 knockdown controls (shRNA) alongside normal samples

The predicted molecular weight of the PHLDA3 protein is 14 kDa , which should be verified during analysis. If studying stress responses, compare PHLDA3 protein levels alongside phosphorylated AKT levels to confirm the functional relationship between these proteins .

How does PHLDA3 function differ from other members of the PHLDA family, and what experimental approaches can distinguish between them?

PHLDA3 belongs to a family that includes PHLDA1 (formerly known as TDAG51) and PHLDA2 (formerly known as IPL). While these proteins share structural similarities, their functional roles differ significantly:

Functional Differences:

• PHLDA3: Functions as a p53/TP53-regulated repressor of Akt/AKT1 signaling by preventing AKT1-binding to membrane lipids . It contributes to p53/TP53-dependent apoptosis and may act as a tumor suppressor .

• PHLDA1: Originally identified as T-cell death-associated gene 51 (TDAG51), it plays roles in apoptosis regulation and cellular differentiation.

• PHLDA2: Identified during searches for the long QT syndrome gene on chromosome 11p15, it has roles in placental growth regulation and embryonic development .

Experimental Approaches to Distinguish Between Family Members:

• Gene Expression Analysis:

  • Design primers with high specificity that target non-homologous regions of each PHLDA family member

  • For PHLDA3-specific RT-PCR, validated primers include:
    Forward: 5'-TGGAGTATAAACGGGGTCTG-3'
    Reverse: 5'-GCAAAGTGAGGAGTGGAATC-3'

  • Verify specificity through sequencing of PCR products

• Protein Detection:

  • Use highly specific antibodies that target unique epitopes

  • For PHLDA3: Mouse monoclonal [4B6] antibody (ab81464) targeting aa 1-50 of human PHLDA3

  • Always validate antibody specificity using overexpression and knockdown controls

• Functional Discrimination:

  • PHLDA3 uniquely inhibits vascular development by blocking AKT activation

  • In contrast to other family members, PHLDA3 plays a protective role during beta cell stress

  • Knockdown studies of individual family members can reveal their specific functions

• Redundancy Analysis:

  • Consider compound knockdown experiments of multiple PHLDA family members

  • When PHLDA3 knockdown shows limited effects, consider possible compensation by PHLDA1 and PHLDA2

When interpreting results from PHLDA family experiments, note that redundancy among family members may mask phenotypes in single-gene knockdown studies, as observed in zebrafish vascular development research .

What methodological approaches are recommended for investigating PHLDA3's role in cellular stress responses?

For comprehensive investigation of PHLDA3's role in cellular stress responses, implement these methodological approaches:

Stress Induction Protocols:

Gene Expression Analysis:

• Quantify PHLDA3 mRNA levels using RT-qPCR in parallel with stress-response genes

• For comprehensive pathway analysis, include markers for:

  • ER stress and UPR: Ddit3, Trb3, Hspa5, Hsp90b1, Fkbp11, Xbp1

  • Antioxidant response: Hmox1, Gpx1, Srxn1

  • Inflammatory signaling: iNos, IL1β, IκBα

Protein Analysis:

• Assess PHLDA3 protein levels via Western blotting

• Evaluate immunostaining intensity using validated antibodies and proper controls

• Analyze phosphorylation status of AKT (Ser473) to confirm functional impact on AKT signaling

Loss-of-Function Studies:

• Implement siRNA-mediated knockdown of PHLDA3

• Assess impact on:

  • Cell viability and apoptosis under stress conditions

  • Expression of inflammatory genes

  • NFκB phosphorylation

  • Antioxidant gene expression

  • Adaptive UPR gene expression

Regulatory Mechanism Investigation:

• Conduct knockdown studies of UPR mediators (Xbp1, Ddit3) to determine their role in PHLDA3 regulation

• Perform rescue experiments using constitutively active AKT to confirm PHLDA3's mechanism of action

This multi-faceted approach allows researchers to comprehensively characterize PHLDA3's role in various stress responses and identify the molecular mechanisms through which it exerts its protective effects in different cellular contexts .

What considerations are important when designing experiments to study PHLDA3's tumor suppressor functions?

When investigating PHLDA3's potential tumor suppressor functions, consider these experimental design principles:

Mechanistic Focus Areas:

• AKT signaling inhibition: PHLDA3 represses AKT1 by preventing its binding to membrane lipids, thereby inhibiting AKT1 translocation and activation

• p53-dependent apoptosis: PHLDA3 contributes to p53/TP53-dependent apoptosis by repressing AKT1 activity

• Direct p53 transcriptional regulation: PHLDA3 is directly regulated by p53, which explains how p53 can negatively regulate AKT1

Experimental Models:

• Use p53-deficient versus p53-competent cell lines to assess PHLDA3 dependence on p53

• Consider MDA-MB-468 cells, which have been validated for PHLDA3 induction studies with Ad-p53

• For in vivo studies, PHLDA3 knockout mice have shown relevant phenotypes including enhanced cell proliferation and improved tolerance to stress

Expression Analysis in Tumor Samples:

• Compare PHLDA3 expression levels between normal and tumor tissues

• Correlate expression with clinical outcomes and p53 status

• Validate using immunohistochemistry with optimized antibodies such as goat polyclonal anti-PHLDA3 (ab22822)

Functional Assays:

• Cell proliferation: Assess impact of PHLDA3 overexpression versus knockdown

• Apoptosis: Measure responses to stress inducers with and without PHLDA3

• Colony formation: Evaluate anchorage-independent growth capabilities

• Migration/invasion: Determine impact on metastatic potential

Signaling Pathway Analysis:

• Analyze AKT phosphorylation status (Ser473) using validated antibodies

• Examine downstream AKT targets including GSK3β, which has been implicated in PHLDA3 function

• Verify protein-protein and protein-lipid interactions through co-immunoprecipitation or lipid binding assays

Technical Considerations:

• Include appropriate positive controls for PHLDA3 induction, such as Ad-p53 treatment

• Implement both gain-of-function (overexpression) and loss-of-function (knockdown) approaches

• For PHLDA3 knockdown, validated shRNA approaches have been documented

• When analyzing Western blot results, the expected molecular weight for PHLDA3 is 14 kDa

By comprehensively investigating these aspects, researchers can establish PHLDA3's role as a tumor suppressor and potentially identify therapeutic strategies targeting this pathway in cancer treatment.

How can researchers troubleshoot non-specific binding issues when using PHLDA3 antibodies?

When encountering non-specific binding with PHLDA3 antibodies, implement these systematic troubleshooting steps:

Antibody Selection and Validation:

• Verify antibody specificity using PHLDA3 overexpression and knockdown controls

• Mouse monoclonal PHLDA3 antibody [4B6] (ab81464) has been validated for human PHLDA3 detection in Western blotting

• For immunostaining, goat polyclonal anti-PHLDA3 antibody (ab22822) used at 1:70 dilution has shown good specificity

Sample Preparation Optimization:

• Ensure complete protein denaturation for Western blotting

• For PHLDA3 detection, 10% SDS-PAGE gels provide optimal resolution for the 14 kDa protein

• When working with tissue samples, optimize extraction protocols to minimize protein degradation and maximize PHLDA3 retrieval

Blocking Optimization:

• Increase blocking time and concentration (5% BSA has shown good results)

• Test alternative blocking agents if non-specific binding persists

• For immunohistochemistry, ensure thorough inactivation of endogenous peroxidases with 3% H₂O₂

Antibody Dilution Optimization:

• Test multiple dilution series, starting with manufacturer recommendations:

  • For Western blotting: 1:1000 primary, 1:20,000 secondary

  • For immunostaining: 1:70 in 1% BSA for goat polyclonal anti-PHLDA3 (ab22822)

• Include appropriate negative controls (secondary antibody only, isotype controls)

Enhanced Washing Protocols:

• Extend washing times between antibody incubations

• Increase the number of wash steps

• Consider using higher detergent concentrations in wash buffers

Positive Control Strategy:

• Include samples from cells treated with known PHLDA3 inducers:

  • Ad-p53 treated MDA-MB-468 cells

  • Cells/islets treated with cytokines, palmitate, thapsigargin, or ribose

  • These treatments significantly upregulate PHLDA3, providing clear positive controls

If non-specific binding persists despite these optimizations, consider alternative detection methods such as mass spectrometry-based approaches or epitope-tagged PHLDA3 expression systems for initial characterization before returning to antibody-based detection.

What are the most effective strategies for studying PHLDA3 interactions with the AKT signaling pathway?

To effectively study PHLDA3 interactions with the AKT signaling pathway, implement these validated research strategies:

Phosphorylation Analysis:

• Assess AKT activation status through western blot analysis using:

  • Anti-phosphorylated-AKT (Ser473) antibody (Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb #4060) at 1:1000 dilution

  • Anti-total AKT antibody (Akt Antibody #9272) at 1:1000 dilution

• Compare phospho-AKT/total AKT ratios between experimental conditions

Gain and Loss of Function Approaches:

• PHLDA3 Overexpression:

  • In zebrafish models, mRNA injection has successfully demonstrated PHLDA3's inhibitory effect on AKT signaling

  • In cell culture, transfection with PHLDA3 expression constructs allows analysis of dose-dependent effects

• PHLDA3 Knockdown:

  • siRNA approaches have been validated in beta cell models

  • shRNA targeting PHLDA3 has been documented in cancer cell lines

Rescue Experiments:

• Use constitutively active forms of AKT to determine if they can reverse phenotypes caused by PHLDA3 overexpression

• This approach has successfully demonstrated that PHLDA3 impairs vascular development specifically through AKT inhibition

Membrane Translocation Assays:

• Since PHLDA3 prevents AKT binding to membrane lipids , assess AKT membrane localization through:

  • Subcellular fractionation followed by Western blotting

  • Immunofluorescence microscopy to visualize AKT localization patterns

  • GFP-tagged AKT constructs for live-cell imaging

Downstream Target Analysis:

• Evaluate activation status of AKT substrates:

  • GSK3β phosphorylation, which has been implicated in PHLDA3 function

  • FOXO transcription factors

  • mTOR pathway components

Lipid Binding Competition Assays:

• Since PHLDA3 competes with the PH domain of AKT for lipid binding , design experiments to measure:

  • Direct lipid binding using purified proteins

  • Competition assays between PHLDA3 and AKT PH domains

  • Structural studies of the interaction interfaces

Stress Response Context:

• Investigate PHLDA3-AKT interactions under various stress conditions:

  • Inflammatory stress (cytokines)

  • Metabolic stress (palmitate, high glucose)

  • ER stress (thapsigargin)

  • Oxidative stress (ribose, H₂O₂)

By combining these approaches, researchers can comprehensively characterize how PHLDA3 regulates AKT signaling in different cellular contexts and under various stress conditions, providing insights into its potential therapeutic applications.

What emerging areas of PHLDA3 research show the most promise for therapeutic development?

Several emerging areas of PHLDA3 research demonstrate significant potential for therapeutic development:

Diabetes and Beta Cell Protection:

• PHLDA3 expression is markedly upregulated in the islets of diabetic humans and mice

• It plays a protective role during beta cell stress by regulating inflammatory gene expression and maintaining antioxidant and adaptive UPR gene expression

• This protective function suggests PHLDA3 as a potential therapeutic target for preserving beta cell function in diabetes

• Research directions:

  • Development of small molecules that enhance PHLDA3 function in beta cells

  • Gene therapy approaches to maintain appropriate PHLDA3 levels

  • Biomarker applications for beta cell stress in prediabetes and diabetes progression

Cancer Therapeutics:

• PHLDA3 functions as a p53-regulated repressor of AKT signaling and may act as a tumor suppressor

• Research directions:

  • Screening for compounds that mimic PHLDA3's inhibitory effect on AKT

  • Developing strategies to enhance PHLDA3 expression in p53-competent tumors

  • Combination therapies targeting both PHLDA3 and p53 pathways

  • Biomarker applications for cancer prognosis and treatment response prediction

Vascular Development and Diseases:

• PHLDA3 regulates hemangioblast specification and vascular development through AKT signaling modulation

• Research directions:

  • Therapeutic targeting of PHLDA3 in vascular malformations

  • Applications in tissue engineering to control vascularization

  • Potential roles in ischemic diseases and stroke recovery

Stress Response Modulation:

• PHLDA3 is induced by various cellular stresses including inflammatory, ER, and oxidative stress

• Its expression is differentially regulated by adaptive (Xbp1) and apoptotic (Ddit3) UPR mediators

• Research directions:

  • Developing modulators of PHLDA3 activity to enhance cellular stress resistance

  • Applications in degenerative diseases characterized by chronic cellular stress

  • Biomarker development for stress response capacity in various tissues

Technical Advances Needed:

• Development of higher-specificity antibodies for various applications and species

• Small molecule modulators of PHLDA3 activity

• Structural studies of PHLDA3-lipid interactions to enable rational drug design

• Improved animal models with tissue-specific PHLDA3 modulation

These research directions represent promising avenues for translating the basic science understanding of PHLDA3 function into therapeutic applications for various diseases including diabetes, cancer, and vascular disorders.

How might single-cell analysis techniques advance our understanding of PHLDA3 function in heterogeneous tissues?

Single-cell analysis techniques offer powerful approaches to advance our understanding of PHLDA3 function in heterogeneous tissues, addressing several key questions that traditional bulk tissue approaches cannot resolve:

Cell Type-Specific Expression Patterns:

• Single-cell RNA sequencing (scRNA-seq) can reveal differential PHLDA3 expression across cell types within:

  • Pancreatic islets, where PHLDA3 has shown protective effects during stress responses

  • Vascular tissues, where PHLDA3 affects development and function

  • Tumor microenvironments, where PHLDA3 may act as a tumor suppressor

• This approach can identify specific cellular populations where PHLDA3 plays the most critical roles

Stress Response Heterogeneity:

• Using scRNA-seq before and after stress exposure can reveal:

  • Which cell subtypes upregulate PHLDA3 most strongly during stress

  • Correlation between PHLDA3 expression and cell survival outcomes

  • Co-expression patterns with other stress response genes (Ddit3, Xbp1, Hmox1)

• This information would help target therapeutic interventions to the most relevant cell populations

Methodological Approaches:

• Single-cell RNA sequencing:

  • Use droplet-based or plate-based platforms to capture thousands of individual cells

  • Include stress conditions such as cytokine exposure, palmitate treatment, or thapsigargin

  • Analyze co-expression patterns between PHLDA3 and known stress-response pathways

• Single-cell protein analysis:

  • Mass cytometry (CyTOF) incorporating PHLDA3 antibodies

  • Single-cell Western blotting to detect PHLDA3 and phosphorylated AKT in the same cells

  • Imaging mass cytometry for spatial context of PHLDA3 expression within tissues

• Spatial transcriptomics:

  • Correlate PHLDA3 expression patterns with tissue architecture and microenvironmental features

  • Particularly relevant for understanding vascular development effects and tumor microenvironment interactions

Research Questions Addressable Through Single-Cell Approaches:

These single-cell approaches would significantly advance our understanding of PHLDA3's role in tissue heterogeneity and could identify previously unrecognized cell populations that might be particularly relevant for therapeutic targeting in diseases such as diabetes and cancer.